Ultrasound turns anticancer molecule into deep-lung bacteria killer

An anticancer medication called TLD1433, a ruthenium(II) complex that has entered Phase II trials for conditions such as non-muscle-invasive bladder cancer, is now being repurposed to address one of the biggest public health issues globally—bacterial infections.

Despite being preventable or treatable in many cases, bacterial infections kill an estimated 7.7 million people each year, resulting in one in eight deaths worldwide.

With these numbers, it stands as the second-leading cause of death on the planet. ...